This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2543 V3 | October 2024

Prescribing information and adverse event reporting statement can be found in the footer

This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2543 V3 | October 2024

Prescribing information and adverse event reporting statement can be found in the footer

Education & Training

To help you help your patients, Flynn Pharma provides useful, informative
and focussed clinical tools and patient support materials that can help to
answer those questions that may pop up in consultation.

Add to favourites
For Healthcare Professionals
Slenyto® Treatment Goals and Therapy Optimisation – A Guide for Healthcare Professionals

Insomnia in children with ASD is perceived to be one of the most challenging health effects of autism and a successful intervention needs to define realistic and agreed outcomes that can be systematically monitored. This simple guide provides healthcare professionals with a concise summary, including a treatment algorithm, to enable treatment with Slenyto® to be optimised.

PRODUCT: Slenyto®
Download See all Resources

Related Education and Training items

Interactive Case Study – Insomnia in Paediatric ASD

An interactive case study for healthcare professionals exploring why insomnia in ASD is a priority, the importance of sleep and how to achieve positive outcomes.
Find out more

4 Reasons to Stop Prescribing Liquid Melatonin for Children

There is a general acceptance of the benefits of solid dosage forms over liquid dosage forms for stability, dosing, and administration issues1. This booklet provides healthcare professionals with a concise summary of the drawbacks of prescribing liquid melatonin in children, with the support of clinical data. 1. European Medicines Agency, Guideline on pharmaceutical development of medicines for paediatric use, 2013. (Accessed November 2022)
Find out more

Slenyto® Therapeutic Bulletin

A succinct summary of the evidence-base for Slenyto® (paediatric prolonged-release melatonin) for the treatment of insomnia in children and adolescents with Autistic Spectrum Disorder and/ or Smith-Magenis Syndrome.

Find out more
More Education & Training